Open Access
Subscription or Fee Access
Role of a Clinical Pharmacist in Attaining Medication Adherence in Oncology Department
Abstract
A Clinical pharmacist aims to contribute to safe medication use by providing comprehensive management to patients and medical staff, both in the community and the hospital. In oncology, these services include comprehensive medication reviews integrating chemotherapy, supportive care and treatment for co-morbidities, medication information for the medical staff and patients, therapeutic drug monitoring anticancer agents, supportive care counseling (nutritional support, pain management, chemotherapy side-effects prophylaxis and treatment), elaboration of therapeutic guidelines. Clinical pharmacists with oncology training have the potential to optimize drug use both in the hospital and the community. With the understanding and recognition of drug interactions and side-effects, pharmacists can provide timely interventions and information to health providers, as well as counseling to patients. From the pharmacist’s point of view and when compared to other clinical disciplines, oncology is characterized by the rapid availability of numerous, costly anticancer agents with new mechanisms of action and sometimes very narrow. Conclusion: As oral anti-cancer agents are gaining great fame all over the world, they are expected to signify up to 25% of all medications used for the mitigation of cancer in future decade. This study demonstrates the central role of a pharmacist that can be reflected in providing patient education regarding missed dose, monitoring and coordinating among health care providers, dispensers and communication with patients.
Keywords
References
V J O'Neill, et al. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer. 2002 Oct 21;87(9):933-7.
Lonneke Timmers, Christel C. L. M. Boons, Femke Kropff. Adherence and patients’ experiences with the use of oral anticancer agents. Acta Oncologica, 2014; 53(2): 259–267.
Caroline Streicher, Pharm D, Annick Daulange, Pharm D. Implementation of pharmacist consultations as part of a multidisciplinary consultation program for patients with oral anticancer agent a descriptive study. European Journal of Oncology Pharmacy. 2008;1(2): p e0003.
Dominique Leveque, Amina Delpeuch and Benedicte Gourieux. New Anticancer Agents: Role of Clinical Pharmacy Services. Anticancer research, 2014; 34(4): 1573-1578.
Susan Goodin, Pharm D, Niesha Griffith, MS, Beth Chen, Pharm D, Karen Chuk, BSc Phm, Mikael Daouphars, Pharm D et.al Safe Handling of Oral Chemotherapeutic Agents in Clinical Practice: Recommendations from an International Pharmacy Panel American Society of Clinical Oncology,2011;7(1): 7-12.
Swart EL, Boons CC, the use of capecitabine in daily practice: a study on adherence and patients' experiences; Patient Prefer Adherence; 2012; 6, 741-8.
Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008; 11(1):44–47.
Ruddy K, Mayer E, Partridge A. Patient adherence and persis tence with oral anticancer treatment. CA Cancer Journal Clin. 2009; 59(1):56–66.
Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. Journal of National Cancer Institute. 2002; 94(9):652–661.
Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. Journal of Clinical Oncology. 1993;Vol 11(6):1189–1197.
Lars Osterberg, M.D., and Terrence Blaschke, M.D. Adherence to Medication. The New England Journal of Medicine. 2005; 353(5):487-97.
Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002; 16(2):269-77.
Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient noncompliance? Hypertension 1980; 2(6):757-64.
Wagner JH, Justice AC, Chesney M, Sinclair G, Weissman S, Rodriguez-Barradas M. Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. Journal of Clinical Epidemiology 2001;54:Suppl 1:S91-S98.
Alcoba M, Cuevas MJ, Perez-Simon MR, et al. Assessment of adherence to triple antiretroviral treatment including indinavir: role of the determination of plasma levels of indinavir. J Acquir Immune Defic Syndr 2003; 33(2):253-8.
Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261(22):3273-7.
Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. Journal of Clinical Epidemiology 1997; 50(1):105-16.
Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of non Adherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009; 113(22):5401–5411.
Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. Journal of Clinical Oncology. 2003; vol- 21(4):602–606.
B G Nagavi, R Adepu, Attitudes and behaviors of practicing community pharmacists towards patient counselling., 2009:71(3):285-289
Becker M H, Maiman LA. Strategies for enhancing patient compliance. Journal of community health. 1980; 6(2): 113-135.
Bloom BS. Daily regimen and compliance with treatment. British Medical Journal 2001; 323(7314): 647.
Alan M.Delamater, Improving Patient Adherence; Clinical Diabetes 2006 Apr; 24(2): 71-77.
Hatoum HT, Hutchinson RA, Lambert BL, Obra 90: Patient counseling-enhancing patient outcome. US pharmacist.1993; 18(1): 38-45.
P.Micheal, Chris L. Bryson, Medication adherence: its importance in cardiovascular outcomes. Circulation 2009 Jun 16; 119(23): 3028-35.
Sonal sekharnM, Suja Abraham; Emerging trends in practice of patient counseling- Indian Scenario: Indian Journal of Pharmacy Practice. 2008; 1(1): 6-13
Vermiere E, et al. Patient Adherence to treatment: Three decades of research. A comprehensive review. Journal of Clinical Pharmacy and Therapeutics, 2001; 26(5): 331-42.
Mélanie White-Koning, et al. Compliance to treatment of adolescents with cancer. Bull Cancer. 2007 Apr; 94(4): 349-56
Debra Winkeljohn. Adherence to oral cancer therapies: nursing interventions. Clin J Oncol Nurs. 2010 Aug; 14(4): 461-6.
Lui G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology 1997; 15(1): 110-5.
Love RR, Cameron L, Connel BL, Leventhal H. Symptoms associated with tamoxifen treatment in post-menopausal women. Arch Intern Med 1991; 151(9):1842-7.
Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence use of lipid lowering medications: A cross national study. JAMA 1998; 279(18): 1458-62.
Lonneke Timmers, Eleonora L Swart, C hristel CLM Boons, Dirk Mangnus, Peter M van de Ven, Godefridus J Peters, Epie Boven, Jacqueline G Hugtenburg. Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice. Front Pharmacol. 2016 Sep 21; 7: 310.
Nilsson JLG, Andersson K, Bergkvist A, Bjorkman I, Brismar A, Moen J. Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients. European Journal of Cancer Care (Engl). 2006; 15(3): 235–237.
Goodman and Gilman’s. The pharmacological basis of therapeutics, 11th edition, pg no: 1320-1321.
Adherence evaluation of endocrine treatment in breast cancer: methodological aspects. BMC Cancer. 2012 Oct 15; 12: 474.
Pitot HC: The molecular biology of carcinogenesis. Cancer. 1993 Aug 1; 72(3 Suppl): 962-70.
Assessing Toxicity in Cancer Chemoprevention Trials: The Other Side of the Coin. Cancer Prev Res 2008; 1(7) December 2008.
KD Tripathi. Essentials of Medical Pharmacology, 6th Ed: 820- 825.
Klausmeier, Nieshi Griffith, MS Susan Goodin, Safe handling oral chemotherapeutic agents, A European prospective. European Journal of Oncology Pharmacy,. 2011, Vol.7(1):7-12.
Sim MH, Leow YC and Chan. Safe handling of oral anti-cancer drugs, Perspective from breast cancer patients At NCC; Journal of oncology pharmacy practice, vol 15: no 3; 2009.
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self- reported measure of medication adherence. Med Care. 1986; 24(1): 67-74.
Morisky DE, Ang Alfonso, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. Journal C linical Hypertens (Greenwich). 2008 May; 10(5): 348-354.
Winterhalder R, Hoesli P, Delmore G. Self-reported compliance with capecitabine: findings from a prospective cohort analysis. Oncology. 2011; 80(1-2): 29-33.
Smith SD, Roasen D, Trueworthy RC, Lowman JT. A reliable method for evaluating drug compliance in children with cancer. 1979; 43(1): 169-73.
Samuel Uretsky, Anticancer Drugs (e-book); 2008.
Polovich, M. Safe handling of Hazardous drugs, Online Journal of Issues in Nursing. 2004, 9(3); 6.
Department of Health and Human Services, NIOSH List of Antineoplastic and other Hazardous Drugs in Healthcare Settings 2012.
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Research & Reviews: Journal of Oncology and Hematology